JP Morgan Chase
RIGL icon

JP Morgan Chase’s Rigel Pharmaceuticals RIGL Stock Holding History

JP Morgan Chase’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,750
Closed -$173K – 5970
2019
Q1 		$173K Sell
6,750
-3,250
-33% -$74.3K ﹤0.01% 4685
2018
Q4 		$230K Hold
10,000
– – ﹤0.01% 4527
2018
Q3 		$321K Buy
+10,000
New +$300K ﹤0.01% 4497

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's RIGL Position: Q1 2026 in Review

JP Morgan Chase increased its Rigel Pharmaceuticals (RIGL) stake by 11% in Q1 2026, buying an estimated $137K and bringing the position to 41,084 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #4578.

JP Morgan Chase first reported a position in RIGL in Q2 2013 and has held it in 43 quarters since. The position peaked at $7.94M in Q3 2016. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • JP Morgan Chase held 41,084 shares of Rigel Pharmaceuticals worth $1.06M as of Q1 2026.
  • JP Morgan Chase bought 4,070 Rigel Pharmaceuticals shares in Q1 2026, an estimated $137K.
  • Rigel Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4578 holding.
  • JP Morgan Chase first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • JP Morgan Chase's Rigel Pharmaceuticals position peaked at $7.94M in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.